Table 2.
Abnormal health observations after treatment initiation presented as total number and rate (%)1
| Clinical system | Clinical sign | Lubabegron2 dose, mg·kg−1 DM | ||||
|---|---|---|---|---|---|---|
| Control | 1.5 | 3.5 | 5.5 | Ptrt3 | ||
| Musculoskeletal | Lameness | 7 (1.0) | 9 (1.3) | 3 (0.4) | 7 (1.0) | 0.444 |
| Gastrointestinal | Bloat4 | 0 | 1 (0.1) | 4 (0.6) | 2 (0.3) | ≥0.124 |
| Respiratory | Pneumonia | 3 (0.4) | 4 (0.6) | 6 (0.8) | 2 (0.3) | 0.539 |
| Removals5 | 12 (1.7) | 18 (2.5) | 11 (1.5) | 13 (1.8) | 0.547 | |
| General | Dead6 | 1 (0.1) | 2 (0.3) | 5 (0.7) | 2 (0.3) | 0.379 |
160 hd per pen; 12 pens per treatment; 720 total hd per treatment. Rate (%) of abnormal health was calculated based on 720 hd per treatment.
2Experior, Elanco, Greenfield, IN, USA.
3Significant effect: Ptrt ≤ 0.10.
4Health observations did not converge, therefore, Fisher’s Exact Test for each contrast was performed where animal was the experimental unit. The total number of animals per dose group was 720 hd.
5Removals include animals found dead (i.e., System: General; Sign: Dead) and all animals removed from study during the treatment phase.
6Animals found dead.